Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...

TauRx was an early proponent of the notion that tau protein could be a legitimate drug target in Alzheimer's, since it was taken up by a lot of larger companies, including Roche/UCB, Johnson ...